Esperion Q2 U.S. product revenue +49% to $20.3M; net loss narrows to $49.9M

Esperion Therapeutics, Inc.

2023-Q2 EPS reported -$1.19 revenue$50,115,000

Total revenue $25.8M (+37% YoY); U.S. net product revenue $20.3M (+49% YoY) driven by 26% retail Rx growth.
Net loss $49.9M ($0.46 per share) versus $66.3M ($1.05) in Q2 2022; R&D expenses fell 32% to $22.1M.
Submitted FDA sNDAs and EMA application to expand NEXLETOL/NEXLIZET labels; approvals expected 1H 2024.
Presented CLEAR Outcomes primary prevention analysis at ADA, published in JAMA, expanding addressable U.S. market to 70M patients.
Cash and investments $138.5M as of June 30, 2023; full-year 2023 opex outlook reaffirmed at $225-245M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Esperion Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $25.8 million, net income $49.9 million, EPS $0.46.

Period: second quarter ended June 30, 2023
Revenue: $25.8 million
Net income: $49.9 million
EPS: $0.46
Result: reported results

Exact text from the filing

Outcomes Analysis by Glycaemic Status, presented by Kausik K Ray. Second Quarter and YTD 2023 Financial Results Total revenue for the second quarter ended June 30, 2023, was $25.8 million and $50.1 million for the six months ended June 30, 2023, compared to $18.8 million and $37.7 million for the comparable periods in 2022, an increase of 37% and 33%,

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-026339

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.